Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis
Pediatric Pulmonology · 2023-08 · 58 (8) · 2308-2316
DOI: 10.1002/ppul.26485 ↗At a glance
Journal article in Pediatric Pulmonology, published online on 2023-05-24. Written by Courtney Gushue and 6 co-authors. Institution: Departments of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA. Major MEDLINE topics: Cystic Fibrosis. Cited 37 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (original language)
Background
In people with cystic fibrosis (pwCF), the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, such as Elexacaftor–Tezacaftor–Ivacaftor (ETI), on structural changes in the lungs is unclear.
Objective
To determine the impact of ETI on clinical parameters and on structural lung disease as measured by the changes in the chest computed tomography (CT) scans in pwCF.
Methods
Percent predicted forced expiratory volume in one second (ppFEV1), body mass index (BMI), and microbiologic data were collected at initiation and 3‐month intervals for 1 year. Chest CT scans before starting ETI therapy (baseline) and at 1‐year on ETI therapy were compared by two pulmonologists independently.
Results
The sample size was 67 pwCF, 30 (44.8%) males, median age of 25 (16, 33.5) years. Significant increases in ppFEV1 and BMI observed by 3 months of ETI therapy persisted throughout 1 year of ETI therapy ( p < 0.001 at all‐time points for both). After 1 year on ETI, pwCF had significant reductions in Pseudomona s aeruginosa (−42%) and MRSA (−42%) positivity. None of the pwCF had worsening of chest CT parameters during 1 year of ETI therapy. Comparing chest CT findings at baseline and at 1‐year follow‐up, bronchiectasis was present in 65 (97%) pwCF and at 1‐year follow‐up decreased in 7 (11%). Bronchial wall thickening 64 (97%), decreased in 53 (79%). Mucous plugging in 63 (96%), absent in 11 (17%), and decreased in 50 (77%). Hyperinflation/air trapping in 44 (67%), decreased in 11 (18%), absent in 27 (44%)
Conclusions
ETI significantly improved clinical outcomes and lung disease as documented by improvement in chest CT scans.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departments of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
- Division of Pulmonary Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA.
- Nationwide Children's Hospital, Columbus, Ohio, USA.
- Biostatistics Resource, The Ohio State University College of Medicine, Columbus, Ohio, USA.
ORCID profiles: Karen McCoy, Shahid Sheikh
Funding
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Cite
APA
Gushue, C., Eisner, M., Bai, S., Johnson, T., Holtzlander, M., McCoy, K., & Sheikh, S. (2023). Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis. Pediatric Pulmonology, 58(8), 2308-2316. https://doi.org/10.1002/ppul.26485
Vancouver
Gushue C, Eisner M, Bai S, Johnson T, Holtzlander M, McCoy K, et al. Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis. Pediatric Pulmonology. 2023;58(8):2308-2316. doi:10.1002/ppul.26485
BibTeX
@article{Gushue2023,
author = {Gushue, Courtney and Eisner, Mariah and Bai, Shasha and Johnson, Terri and Holtzlander, Melissa and McCoy, Karen and Sheikh, Shahid},
title = {Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis},
journal = {Pediatric Pulmonology},
year = {2023},
volume = {58},
number = {8},
pages = {2308--2316},
doi = {10.1002/ppul.26485}
}
EUVIMED